TL;DR
This review summarizes the unique pathophysiological features and current therapeutic challenges of immune-mediated necrotizing myopathy and explores the feasibility of CAR-Treg-based approaches for refractory IMNM.
Immune-mediated necrotizing myopathy (IMNM) is a distinct subtype of idiopathic inflammatory myopathies (IIMs), classified by serum autoantibody status into anti-signal recognition particle (anti-SRP)-positive, anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR)-positive, and seronegative subgroups. Its h...
Giant cell myocarditis (GCM) is a rare, rapidly progressive cardiac disorder characterized by giant, multinucleated cells that contribute to severe myocardial damage. Existing combination immunosuppressive therapies, although directed at immune-mediated injury, lack precision and are associated with considerable advers...
PURPOSE OF REVIEW Inclusion body myositis (IBM) is the most common acquired myopathy in individuals over 50 years of age and remains refractory to conventional immunosuppressive therapies. This review summarizes recent advances in the understanding of IBM pathogenesis and highlights emerging therapeutic strategies. R...
Background: Autoimmune rheumatic diseases (ARDs) are characterized by a failure of immune tolerance, leading to chronic inflammation, autoantibody production, and progressive organ damage. Conventional therapies often fail to induce long-term, drug-free remission in refractory patients. Chimeric antigen receptor (CAR)...
Immune checkpoint inhibitors (ICIs) have improved outcomes for cancer patients. However, they can cause toxicities called immune-related adverse events (irAEs). One serious toxicity is the myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome, an inflammatory syndrome involving the heart, skeletal muscles...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
